1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Hepatic - Colorectal Metastasis – Pipeline Review, H1 2013

Hepatic - Colorectal Metastasis – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 33 pages

Hepatic - Colorectal Metastasis – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Hepatic - Colorectal Metastasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hepatic - Colorectal Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatic - Colorectal Metastasis. Hepatic - Colorectal Metastasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatic - Colorectal Metastasis.
- A review of the Hepatic - Colorectal Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hepatic - Colorectal Metastasis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hepatic - Colorectal Metastasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hepatic - Colorectal Metastasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Hepatic - Colorectal Metastasis - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Hepatic - Colorectal Metastasis Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Hepatic - Colorectal Metastasis 6
Hepatic - Colorectal Metastasis Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Early Clinical Stage Products 10
Comparative Analysis 10
Hepatic - Colorectal Metastasis Therapeutics - Products under Development by Companies 11
Companies Involved in Hepatic - Colorectal Metastasis Therapeutics Development 12
Celsion Corporation 12
Amgen Inc. 13
Hepatic - Colorectal Metastasis - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Drug Profiles 19
adecatumumab - Drug Profile 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
doxorubicin heat-sensitive liposomal - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
ALF-5755 - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Hepatic - Colorectal Metastasis Therapeutics - Drug Profile Updates 24
Hepatic - Colorectal Metastasis Therapeutics - Dormant Products 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33



List of Tables

Number of Products Under Development for Hepatic - Colorectal Metastasis, H1 2013 6
Products under Development for Hepatic - Colorectal Metastasis - Comparative Analysis, H1 2013 7
Number of Products under Development by Companies, H1 2013 8
Comparative Analysis by Mid Clinical Stage Development, H1 2013 9
Comparative Analysis by Early Clinical Stage Development, H1 2013 10
Products under Development by Companies, H1 2013 11
Celsion Corporation, H1 2013 12
Amgen Inc., H1 2013 13
Assessment by Monotherapy Products, H1 2013 14
Assessment by Stage and Route of Administration, H1 2013 16
Assessment by Stage and Molecule Type, H1 2013 18
Hepatic - Colorectal Metastasis Therapeutics - Drug Profile Updates 24
Hepatic - Colorectal Metastasis Therapeutics - Dormant Products 31



List of Figures

Number of Products under Development for Hepatic - Colorectal Metastasis, H1 2013 6
Products under Development for Hepatic - Colorectal Metastasis - Comparative Analysis, H1 2013 7
Products under Development by Companies, H1 2013 8
Mid Clinical Stage Products, H1 2013 9
Early Clinical Stage Products, H1 2013 10
Assessment by Monotherapy Products, H1 2013 14
Assessment by Route of Administration, H1 2013 15
Assessment by Stage and Route of Administration, H1 2013 16
Assessment by Molecule Type, H1 2013 17
Assessment by Stage and Molecule Type, H1 2013 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.